The Gene Verification Committee (GVC) reviews published human genetic evidence that specific loci or genes are associated with AD or contribute to AD risk. The GVC uses a four-tier system to evaluate the quality of evidence supporting associations to inform prioritization of loci and genes for investment in functional genomic methods leading to selection of therapeutic targets.
